L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R,R))-

Esophageal Varices

Shanghai Zhongshan Hospitalprotein_peptidePhase 4 / ApprovedDormant

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Esophageal Varices cohort.

Asset / Sponsor	Phase	Rating
Apsolol West China Hospital	Phase 4	BBB
CARVEDILOL West China Hospital	Phase 4	BBB
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) General Hospital of Shenyang Military Region	Phase 4	BB
Apixaban Asian Institute Of Medical Sciences	Phase 4	BB
SIMVASTATIN Universidade Federal do Rio de Janeiro	Phase 3	BB

View all 14 →

Same molecule, other indications

L-CYSTEINAMIDE, D-PHENYLALANYL-L-CYSTEINYL-L-PHENYLALANYL-D-TRYPTOPHYL-L-LYSYL-L-THREONYL-N-(2-HYDROXY-1-(HYDROXYMETHYL)PROPYL)-, CYCLIC (2->7)-DISULFIDE, (R-(R*,R*))- is also rated in:

diarrheal diseaseDormant

Indicative · Phase 3

71 / 100

View asset →

cirrhosis of liverDormant

Indicative · Phase 4

71 / 100

View asset →

hepatocellular carcinomaActive

Indicative · Phase 3

69 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →